Children with obesity-linked health issues such as high cholesterol or sleep apnea are far more likely to receive prescriptions for GLP-1 medications than their peers without these conditions, according to new research. The findings highlight a growing trend in how weight-management drugs are being integrated into pediatric care beyond obesity treatment alone. Experts suggest the shift may reflect broader efforts to address metabolic and respiratory complications in young patients. The data raises questions about long-term safety and appropriate use in children, given the drugs’ primary approval for adult diabetes and weight loss.
Kids with obesity-related conditions like high cholesterol or sleep apnea were substantially more likely to be prescribed GLP-1s than those without.
